Amnah Yamani1, David Wu1, Lisa Waggoner1, Taeko Noah1, Anthony J Koleske2, Fred Finkelman3, Simon P Hogan4. 1. Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio. 2. Department of Biological and Biomedical Sciences, Yale University, New Haven, Conn. 3. Division of Immunobiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio. 4. Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio. Electronic address: simon.hogan@cchmc.org.
Abstract
BACKGROUND: Severe IgE-mediated, food-induced anaphylactic reactions are characterized by pulmonary venous vasodilatation and fluid extravasation, which are thought to lead to the life-threatening anaphylactic phenotype. The underlying immunologic and cellular processes involved in driving fluid extravasation and the severe anaphylactic phenotype are not fully elucidated. OBJECTIVE: We sought to define the interaction and requirement of IL-4 and vascular endothelial (VE) IL-4 receptor α chain (IL-4Rα) signaling in histamine-abelson murine leukemia viral oncogene homology 1 (ABL1)-mediated VE dysfunction and fluid extravasation in the severity of IgE-mediated anaphylactic reactions in mice. METHODS: Mice deficient in VE IL-4Rα and models of passive and active oral antigen- and IgE-induced anaphylaxis were used to define the requirements of the VE IL-4Rα and ABL1 pathway in severe anaphylactic reactions. The human VE cell line (EA.hy926 cells) and pharmacologic (imatinib) and genetic (short hairpin RNA knockdown of IL4RA and ABL1) approaches were used to define the requirement of this pathway in VE barrier dysfunction. RESULTS: IL-4 exacerbation of histamine-induced hypovolemic shock in mice was dependent on VE expression of IL-4Rα. IL-4- and histamine-induced ABL1 activation in human VE cells and VE barrier dysfunction was ABL1-dependent. Development of severe IgE-mediated hypovolemia and shock required VE-restricted ABL1 expression. Treatment of mice with a history of food-induced anaphylaxis with the ABL kinase inhibitor imatinib protected the mice from severe IgE-mediated anaphylaxis. CONCLUSION: IL-4 amplifies IgE- and histamine-induced VE dysfunction, fluid extravasation, and the severity of anaphylaxis through a VE IL-4Rα/ABL1-dependent mechanism. These studies implicate an important contribution by the VE compartment in the severity of anaphylaxis and identify a new pathway for therapeutic intervention of IgE-mediated reactions.
BACKGROUND: Severe IgE-mediated, food-induced anaphylactic reactions are characterized by pulmonary venous vasodilatation and fluid extravasation, which are thought to lead to the life-threatening anaphylactic phenotype. The underlying immunologic and cellular processes involved in driving fluid extravasation and the severe anaphylactic phenotype are not fully elucidated. OBJECTIVE: We sought to define the interaction and requirement of IL-4 and vascular endothelial (VE) IL-4 receptor α chain (IL-4Rα) signaling in histamine-abelsonmurineleukemia viral oncogene homology 1 (ABL1)-mediated VE dysfunction and fluid extravasation in the severity of IgE-mediated anaphylactic reactions in mice. METHODS:Mice deficient in VE IL-4Rα and models of passive and active oral antigen- and IgE-induced anaphylaxis were used to define the requirements of the VE IL-4Rα and ABL1 pathway in severe anaphylactic reactions. The human VE cell line (EA.hy926 cells) and pharmacologic (imatinib) and genetic (short hairpin RNA knockdown of IL4RA and ABL1) approaches were used to define the requirement of this pathway in VE barrier dysfunction. RESULTS:IL-4 exacerbation of histamine-induced hypovolemic shock in mice was dependent on VE expression of IL-4Rα. IL-4- and histamine-induced ABL1 activation in human VE cells and VE barrier dysfunction was ABL1-dependent. Development of severe IgE-mediated hypovolemia and shock required VE-restricted ABL1 expression. Treatment of mice with a history of food-induced anaphylaxis with the ABL kinase inhibitor imatinib protected the mice from severe IgE-mediated anaphylaxis. CONCLUSION:IL-4 amplifies IgE- and histamine-induced VE dysfunction, fluid extravasation, and the severity of anaphylaxis through a VE IL-4Rα/ABL1-dependent mechanism. These studies implicate an important contribution by the VE compartment in the severity of anaphylaxis and identify a new pathway for therapeutic intervention of IgE-mediated reactions.
Authors: Hugh A Sampson; Anne Muñoz-Furlong; S Allan Bock; Cara Schmitt; Robert Bass; Badrul A Chowdhury; Wyatt W Decker; Terence J Furlong; Stephen J Galli; David B Golden; Rebecca S Gruchalla; Allen D Harlor; David L Hepner; Marilyn Howarth; Allen P Kaplan; Jerrold H Levy; Lawrence M Lewis; Phillip L Lieberman; Dean D Metcalfe; Ramon Murphy; Susan M Pollart; Richard S Pumphrey; Lanny J Rosenwasser; F Estelle Simons; Joseph P Wood; Carlos A Camargo Journal: J Allergy Clin Immunol Date: 2005-03 Impact factor: 10.793
Authors: D A Tuveson; N A Willis; T Jacks; J D Griffin; S Singer; C D Fletcher; J A Fletcher; G D Demetri Journal: Oncogene Date: 2001-08-16 Impact factor: 9.867
Authors: Jurjan Aman; Jan van Bezu; Amin Damanafshan; Stephan Huveneers; Etto C Eringa; Steven M Vogel; A B Johan Groeneveld; Anton Vonk Noordegraaf; Victor W M van Hinsbergh; Geerten P van Nieuw Amerongen Journal: Circulation Date: 2012-10-25 Impact factor: 29.690
Authors: Raffi Tachdjian; Clinton Mathias; Shadi Al Khatib; Paul J Bryce; Hong S Kim; Frank Blaeser; Brian D O'Connor; Danuta Rzymkiewicz; Andrew Chen; Michael J Holtzman; Gurjit K Hershey; Holger Garn; Hani Harb; Harald Renz; Hans C Oettgen; Talal A Chatila Journal: J Exp Med Date: 2009-09-21 Impact factor: 14.307
Authors: Frank Blaeser; Paul J Bryce; Nga Ho; Vidya Raman; Fatma Dedeoglu; Debra D Donaldson; Raif S Geha; Hans C Oettgen; Talal A Chatila Journal: J Exp Med Date: 2003-10-13 Impact factor: 14.307
Authors: Taeko K Noah; Kathryn A Knoop; Keely G McDonald; Jenny K Gustafsson; Lisa Waggoner; Simone Vanoni; Matthew Batie; Kavisha Arora; Anjaparavanda P Naren; Yui-Hsi Wang; Nicholas W Lukacs; Ariel Munitz; Michael A Helmrath; Maxime M Mahe; Rodney D Newberry; Simon P Hogan Journal: J Allergy Clin Immunol Date: 2019-06-05 Impact factor: 10.793
Authors: Taeko K Noah; Jee-Boong Lee; Christopher A Brown; Amnah Yamani; Sunil Tomar; Varsha Ganesan; Rodney D Newberry; Gary B Huffnagle; Senad Divanovic; Simon P Hogan Journal: Front Immunol Date: 2021-03-25 Impact factor: 7.561